| PUBLICATIONS (Ranked by impact factor of the journal) | Increased Prevalence of Circulating Novel IL-17 Secreting Foxp3 Expressing CD4+ T Cells and Defective Suppressive Function of Circulating Foxp3+ Regulatory Cells Support Plasticity Between Th17 and Regulatory T Cells in Inflammatory Bowel Disease Patients Scientists investigated the circulating IL-17 and Foxp3 double expressing CD4+ T lymphocytes in patients with inflammatory bowel disease. The entire cohort consisted of 79 subjects: 31 patients with Crohn’s disease, 28 patients with ulcerative colitis, and 20 healthy control subjects. [Inflamm Bowel Dis] Abstract Macrophage Phenotype in the Subclinical Gut Inflammation of Patients with Ankylosing Spondylitis Long-term evolution of subclinical gut inflammation to overt Crohn’s disease has been described in ankylosing spondylitis (AS) patients. The authors aimed to evaluate macrophage polarization occurring in the inflamed gut of patients with AS. [Rheumatology] Abstract Pro-Inflammatory Action of MIF in Acute Myocardial Infarction via Activation of Peripheral Blood Mononuclear Cells Macrophage migration inhibitory factor (MIF), a pro-inflammatory cytokine, has been implicated in the pathogenesis of multiple inflammatory disorders. Scientists determined changes in circulating MIF levels, explored the cellular source of MIF, and studied the role of MIF in mediating inflammatory responses following acute myocardial infarction. [PLoS One] Full Article Adipocytokine Profile, Cytokine Levels and Foxp3 Expression in Multiple Sclerosis: A Possible Link to Susceptibility and Clinical Course of Disease Adipocytokines may be involved in multiple sclerosis (MS) as well as other autoimmune and inflammatory-related diseases. Researchers compared levels of resistin, visfatin and leptin in three subgroups of MS patients with healthy subjects and also studied their relationship with Foxp3 expression and levels of several pro-inflammatory mediators such as interleukin-1 β,tumor necrosis factor-α and human sensitive C-reactive protein. [PLoS One] Full Article General Immune Dampening Is Associated with Disturbed Metabolism at Diagnosis of Type 1 Diabetes An attempt has been made to describe how clinical and immunological deviations might influence each other close to the diagnosis of Type 1 diabetes. [Pediatr Res] Abstract Upregulation of the Inhibitory Receptor ILT4 in Monocytes from Septic Patients Immunoglobulin like transcript 4 (ILT4) expression, endotoxin-induced IL-12 and IL-10 production and CD86 expression were investigated in circulating monocytes from 16 patients with severe sepsis and 16 age and sex matched controls. Researchers found that monocytes from patients with severe sepsis express significantly higher levels of ILT4 than monocytes from controls. [Hum Immunol] Abstract Involvement of Th17 Cells in Patients of Urothelial Carcinoma of Bladder The authors assessed expression of Th17 related cytokines, RORγt and distribution of Th17 cells to understand its involvement in bladder cancer. [Hum Immunol] Abstract | Subscribe to our sister publications: Immunology of Infectious Disease News and Immune Regulation News! |
| INDUSTRY NEWS | Cancer Vaccine Company DCPrime and Janssen to Collaborate on Potential New Therapy DCPrime BV announced that it has entered into a research and optional license agreement with Janssen Pharmaceuticals, Inc. The collaboration has been facilitated in conjunction with the Johnson & Johnson London Innovation Centre, where a team of business, science and transaction experts are identifying and building novel early-stage collaborations with emerging companies. [DCPrime BV] Press Release EMD Serono Makes First Awards as Part of the Company’s One Million Euro Grant for Multiple Sclerosis Innovation EMD Serono, Inc., a subsidiary of Merck KGaA announced the recipients of the company’s inaugural Grant for Multiple Sclerosis Innovation. Four recipients, three from the United States and one from Germany, will share the overall €1 million grant to support their research. [EMD Serono, Inc.] Press Release Xencor’s XmAb5871 Enters Phase IIa Study for Autoimmune Disease Xencor, Inc. announced that the first patient has been dosed in the Phase IIa part of its ongoing Phase Ib/IIa clinical trial of XmAb®5871 in patients with active rheumatoid arthritis. XmAb5871 is the first in Xencor’s class of therapeutic antibodies targeting the FcγRIIb pathway in B cells, which shows potential to suppress autoimmune disorders without the side effects caused by B cell depletion. [Xencor, Inc.] Press Release |
|